Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | P-BCMA-101 CAR-T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). |
DrugClasses | TNFRSF17 Immune Cell Therapy 26 |
CAS Registry Number | NA |
NCIT ID | C142864 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
P-BCMA-101 CAR-T cells | P-BCMA-101 CAR-T cells | 0 | 1 |
P-BCMA-101 CAR-T cells + Rimiducid | P-BCMA-101 CAR-T cells Rimiducid | 0 | 0 |